Market Update Economic Events Directors Deals Commodities Prices News Market Movers

Hvivo eyes further development of mosquito-borne diseases treatment

Wednesday, 31st October 2018
Hvivo said Wednesday partial data from a phase I trial released by the National Institutes of Health showed the company's mosquito-borne diseases treatment required further development.

The presentation of the study focused on the safety and certain immunogenicity results of the company's AGS-v, a mosquito saliva peptide vaccine in a controlled Phase I trial, the company said.

Given the safety profile of the vaccine observed in the study further development of the vaccine would continue, it added.

'The presentation of these partial preliminary results by NIH at the conference is encouraging regarding safety and immunogenicity responses,' said chairman Trevor Phillips.

'We look forward to seeing the full data when the NIH completes the sample analyses in due course, at which point, a full assessment of the trial results will be possible.'

'The remaining primary and secondary results from the phase I study will be evaluated once the full and final data are available'" said hVIVO.

At 8:37am: (LON:HVO) hVIVO Plc share price was +1p at 44p

Story provided by

Related Shares: Hvivo

Share Search
Share Search Share Search

Visit the Share Search.
Share Search

Share News
Share News will do their best to ensure the quality of the information displayed on this site, but all information is provided as-is, free of charge. We cannot be held responsible for any loss, material or otherwise, due to incorrect information found here. UK data supplied by NBTrader and Digital Look. Share Prices are at least 15 minutes delayed.